Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab

Aim: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR). Patients & methods: We co...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Melanoma Management
المؤلفون الرئيسيون: Quaovi H Sodji, Paulina M Gutkin, Susan M Swetter, Sunil A Reddy, Susan M Hiniker, Susan J Knox
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Taylor & Francis Group 2020-05-01
الموضوعات:
hypophysitis
immunotherapy
melanoma
radiation therapy
الوصول للمادة أونلاين:https://www.futuremedicine.com/doi/10.2217/mmt-2019-0020
الوصف
الملخص:Aim: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR). Patients & methods: We continued to follow these patients with serial imaging including computed tomography, PET or MRI. Results: Two of the three patients with CR are still alive and without evidence of melanoma but with chronic treatment-induced hypophysitis. The third patient died of hepatocellular carcinoma, but with no evidence of melanoma. Among the three patients with PR, two achieved CR after pembrolizumab monotherapy. Conclusion: This long-term follow up reveals the striking durability of the CRs, which appears to correlate with a grade 2–3 hypophysitis.
تدمد:2045-0885
2045-0893

مواد مشابهة